Target General Infomation
Target ID
T67207
Former ID
TTDI02068
Target Name
Fc-epsilon-RII (CD23)
Gene Name
FCER2
Synonyms
BLAST2; CD23; Ctype lectin domain family 4 member J; FcepsilonRII; Immunoglobulin Ebinding factor; Low affinity immunoglobulin epsilon Fc receptor; Low affinity immunoglobulin epsilon Fc receptor soluble form; Lymphocyte IgE receptor; FCER2
Target Type
Clinical Trial
Disease Leukemia [ICD9: 208.9; ICD10: C90-C95]
Function
Low-affinity receptor for immunoglobulin E (IgE) and CR2/CD21. Has essential roles in the regulation of IgE production and in the differentiation of B-cells (it is a B-cell-specific antigen).
BioChemical Class
Immunoglobulin
UniProt ID
Sequence
MEEGQYSEIEELPRRRCCRRGTQIVLLGLVTAALWAGLLTLLLLWHWDTTQSLKQLEERA
ARNVSQVSKNLESHHGDQMAQKSQSTQISQELEELRAEQQRLKSQDLELSWNLNGLQADL
SSFKSQELNERNEASDLLERLREEVTKLRMELQVSSGFVCNTCPEKWINFQRKCYYFGKG
TKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVDGSHV
DYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGSAESM
GPDSRPDPDGRLPTPSAPLHS
Drugs and Mode of Action
Drug(s) Lumiliximab Drug Info Phase 2 Leukemia [521906]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Hematopoietic cell lineage
Epstein-Barr virus infection
NetPath Pathway IL-7 Signaling Pathway
IL3 Signaling Pathway
IL4 Signaling Pathway
Pathway Interaction Database IL4-mediated signaling events
Reactome NOTCH2 intracellular domain regulates transcription
WikiPathways Human Complement System
Signaling by NOTCH2
References
Ref 521906ClinicalTrials.gov (NCT00391066) Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL). U.S. National Institutes of Health.
Ref 527784Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol. 2005 Oct;116(4):780-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.